Tongbiao Zhao

Residual PSC detection follows ultra‑trace‑analysis principles. LOD supports qualitative assessment. Assays employ PSC‑specific markers and proper references, with adaptation to differentiated cell populations from diverse PSC sources.

The overlap HPLC chromatograms of ATP standard (red) and ATP in cells (blue). Poroshell 120 EC-C18 (3 × 150 mm, 2.7 μm), 25°C, pH 6.8 buffer solution of 0.05 mol/L KH₂PO₄ - 0.05 mol/L K₂HPO₄ (V:V = 1:1) as mobile phase, 0.6 mL/min, 254 nm.

This guideline establishes a comprehensive framework for the application of patient-derived pancreatic cancer organoids. It outlines the stringent technical requirements and testing methods necessary to ensure high fidelity to the original tumor tissue, including morphological assessment, pathological biomarker expression (e.g., CK19, CK7), and genetic concordance (e.g., NRG1, KRAS). By standardizing protocols for in vitro culture, microbiological safety, and STR authentication, this consensus aims to ensure the reproducibility, safety, and stability of organoid models, thereby accelerating their integration into basic research, drug discovery, and precision medicine.

‘Technical specification for haemocompatibility assessment of human mesenchymal stem cells’ is the first set of guidelines on haemocompatibility assessment of human mesenchymal stem cells (MSCs) in China, jointly drafted and agreed upon by experts from the Chinese Society for Stem Cell Research. This standard outlines the methods for assessing the hemocompatibility of human mesenchymal stem cells and specifies the requirements for the selection of evaluation indicators, calculation of indicator values, and determination of hemocompatibility levels. It is applicable for evaluating the hemocompatibility of MSCs prior to their contact with blood. This guideline was originally released by the Chinese Society for Cell Biology on October 28, 2024. We anticipate that the publication of this specification will promote the institutional adoption, acceptance, and execution of proper testing protocols, thereby accelerating the international standardization of MSCs for clinical development and therapeutic applications.

Although Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable success in treating hematopoietic malignancies, its clinical application in solid tumors is profoundly hindered by persistent T-cell exhaustion within the immunosuppressive tumor microenvironment (TME). Here, we identified SATB1—a genome organizer regulating chromatin architecture—as a key suppressor of CAR-T cell exhaustion. In Glypican-3 (GPC3)-targeted CAR-T cells, SATB1 was significantly downregulated in tumor-infiltrating exhausted populations. SATB1 overexpression not only reduced expression of multiple inhibitory receptors (PD-1, CTLA-4, TIM3, and LAG-3) but also promoted a central memory phenotype, enhancing cytokine production and cytotoxicity against hepatocellular carcinoma (HCC) cells in vitro. In vivo, SATB1-engineered CAR-T cells exhibited superior tumor control and promoted survival, accompanied by reduced exhaustion markers in tumor-infiltrating T cells. These functional improvements are consistent with the reported role of SATB1 in modulating T cell exhaustion, positioning it as a multifunctional enhancer of CAR-T cell fitness. Collectively, our study unveils SATB1 as a multifunctional modulator that simultaneously targets exhaustion and memory differentiation, offering a novel strategy to enhance CAR-T efficacy against solid tumors.